Peritoneal Carcinomatosis of Rare Ovarian Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Multi-Institutional Cohort from PSOGI and BIG-RENAPE-Reference-Cited by-同舟云学术

Peritoneal Carcinomatosis of Rare Ovarian Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Multi-Institutional Cohort from PSOGI and BIG-RENAPE

Published:2018-04-10 Issue:6 Volume:25 Page:1668-1675
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Mercier Frédéric^ORCID, ,Bakrin Naoual,Bartlett David L.,Goere Diane,Quenet François,Dumont Frédéric,Heyd Bruno,Abboud Karine,Marolho Christelle,Villeneuve Laurent,Glehen Olivier,

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/article/10.1245/s10434-018-6464-z/fulltext.html

Reference43 articles.

1. Neijt JP. New therapy for ovarian cancer. N Engl J Med. 1996;334:50–1.

2. Bhatt A, Glehen O. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer: a review. Indian J Surg Oncol. 2016;7(2):188–97.

3. Sehouli J, Senyuva F, Fotopoulou C, Neumann U, Denkert C,Werner L, Gülten O. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol. 2009;99(7):424–7.

4. Bamias A, Psaltopoulou T, Sotiropoulou M et al. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer. 2010;116:1462–8.

5. Fung-Kee-Fung M, Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007;14:195–208.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peritoneal metastases from rare ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC);Pleura and Peritoneum;2023-12-27

2. Prognostic role of the peritoneal cancer index in ovarian cancer patients who undergo cytoreductive surgery: a meta-analysis;Current Problems in Cancer;2023-12

3. Extreme Leukocytosis and Gangrenous Cholecystitis Associated with Cytoreductive Surgery and HIPEC-Treated Mucinos Ovary Cancer: Case Report and Literature Review;Clinics and Practice;2023-09-18

4. Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in patients with Advanced Ovarian Cancer: A 2-year survival analysis study;Current Women s Health Reviews;2023-08-22

5. The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Epithelial Ovarian Cancer;Annals of Surgical Oncology;2023-08-10